Brief: Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026 11:29
May 21 (Reuters) - Immix Biopharma Inc IMMX.O: IMMIX BIOPHARMA ANNOUNCES 95% COMPLETE RESPONSE RATE IN INTERIM UPDATE FROM RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL NEXICART-2 IMMIX BIOPHARMA INC - PLANS TO INITIATE PHASE 3 TRIAL IN NEWLY DIAGNOSED AL AMYLOIDOSIS PATIENTS IMMIX BIOPHARMA, INC: NEXT NEXICART-2 UPDATE EXPECTED LATE SEPTEMBER, 2026 IMMIX BIOPHARMA: BY MARCH END 2027, EXPECT TO PRESENT 1-YEAR FOLLOW-UP DATA OF ENROLLED PATIENTS; SEES IT TO DRIVE BLA SUBMISSION, COMMERCIAL LAUNCH Source text: ID:nGNXQRLX Further company coverage: IMMX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary